Vaso Corporation Stocks

$ 0.18Last Updated 30.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 32.87M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.18
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, undervalued on P/F

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks